Mink Therapeutics, INC 8-K filings

MiNK Therapeutics announced second quarter 2026 financial results and provided positive initial observations from its Phase 2 trial of agenT-797 in acute lung injury, alongside establishing a paid international named-patient access program.

MiNK Therapeutics announced first quarter 2026 financial results, highlighting the initiation of a Phase 2 trial for agenT-797 in acute lung injury and advancements in its iNKT cell therapy platform.

MiNK Therapeutics reported Q4 and full-year 2025 financial results, highlighting advancements in its Phase 2 programs for ARDS and GVHD, bolstered by significant non-dilutive funding.

MiNK Therapeutics addresses investor inquiries, confirming active discussions for agenT-797 combination trials and strategic investments.

MiNK Therapeutics announced the appointment of Melissa Orilall as Principal Financial Officer and Austin Charette as Principal Accounting Officer, effective March 13, 2026.

Dr. Robert Kadlec has resigned from MiNK Therapeutics' Board of Directors to accept a senior public service position within the U.S. government.

MiNK Therapeutics reported Q3 2025 financial results, highlighted durable clinical responses for agenT-797, expanded its iNKT platform, and strengthened its leadership team, extending its cash runway through 2026.

MiNK Therapeutics strengthens its Board of Directors with the appointment of Dr. John Holcomb, a renowned expert in trauma and critical care, to accelerate iNKT cell therapies.

MiNK Therapeutics announced its second quarter 2025 financial results and significant clinical and strategic milestones, including extended cash runway and new grant funding.

MiNK Therapeutics, Inc. has entered into an At Market Issuance Sales Agreement with B. Riley Securities, Inc. to sell up to $50 million of its common stock, providing a flexible capital raising mechanism.

MiNK Therapeutics announced significant positive clinical data for its allogeneic iNKT cell therapy, agenT-797, including a complete and durable remission in metastatic testicular cancer and promising early signals in gastric cancer.

MiNK Therapeutics, Inc. announced that its stockholders approved all three proposals, including the re-election of two Class I directors and the ratification of KPMG LLP as its independent auditor, at the Annual Meeting held on June 18, 2025.

MiNK Therapeutics reports Q1 2025 results, highlighting clinical progress with agenT-797 and strategic discussions to bolster liquidity.

MiNK Therapeutics announced its Q4 and full year 2024 financial results, showcasing clinical progress, manufacturing enhancements, and strategic collaborations.

MiNK Therapeutics will implement a 1-for-10 reverse stock split, effective January 28, 2025, to increase its stock price.

MiNK Therapeutics reported its third quarter 2024 financial results, highlighted by progress in clinical programs and strategic collaborations.

MiNK Therapeutics has appointed Dr. Robert Kadlec, a former Assistant Secretary for Preparedness and Response, to its Board of Directors to leverage his expertise in public health and biodefense.

MiNK Therapeutics' Chief Scientific Officer, Dr. Marc Van Dijk, will transition to a Scientific Advisory Board Member and Strategic Consultant role effective November 15, 2024.

MiNK Therapeutics has received a notice from Nasdaq for failing to maintain the minimum market value of listed securities, putting it at risk of delisting.

MiNK Therapeutics received a notice from Nasdaq stating the company failed to regain compliance with the minimum bid price requirement and is now subject to potential delisting.

MiNK Therapeutics reported its second quarter 2024 financial results, highlighted by advancements in its iNKT cell therapy programs, including agenT-797, and a successful private placement financing.

MiNK Therapeutics held its annual meeting on June 12, 2024, where stockholders elected two Class III directors and ratified the appointment of KPMG LLP as the company's independent auditor.

MiNK Therapeutics has successfully raised approximately $5.8 million through a private placement of common stock at a 25% premium to the 30-day volume-weighted average price.

MiNK Therapeutics reported its first quarter 2024 financial results, highlighted by a $5.8 million private placement and progress in its iNKT cell therapy programs.

MiNK Therapeutics reported its fourth quarter and full-year 2023 financial results, highlighting progress in its allogeneic iNKT cell therapy programs, including the launch of a Phase 2 trial for agenT-797 in gastroesophageal cancers.

MiNK Therapeutics has received notices from Nasdaq for failing to meet the minimum market value and share price requirements for continued listing.

MiNK Therapeutics has entered into a convertible promissory note agreement with Agenus Inc., securing up to $5 million in funding.